Outcome of Innate Pharma’s 2022 Annual General Meeting
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has announced the results of its Annual General Meeting (AGM) held on May 20, 2022, in Marseille, France. A quorum of 40.88% was reached with 134 votes cast from a total of 32,598,725 shares. Notably, Dr. Sally Bennett has been appointed to the Supervisory Board and will also serve on the Audit Committee. She brings over 20 years of experience in finance and life sciences. Additionally, Mr. Patrick Langlois has resigned from the Board after 12 years of service.
- Appointment of Dr. Sally Bennett, enhancing board expertise.
- Dr. Bennett's extensive experience in finance and biopharmaceuticals is expected to contribute positively to strategic goals.
- Resignation of Patrick Langlois may lead to a temporary gap in board experience.
Appointment of Dr
A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of
The resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2022 section of the Company’s website.
The Company’s 2021 20-F is available on the Investors section of the website.
As part of the resolutions voted by shareholders, Dr
“We are very pleased to welcome Dr
Dr.
Today, Mr
"Patrick has been a valued member of the Supervisory Board and we are grateful for his important contribution over the past twelve years. On behalf of the Supervisory Board, I would like to thank him for his commitment over the years and wish him all the best for the future,” said
To date, the Supervisory Board of
-
Hervé Brailly , Chairman -
Irina Staatz-Granzer , Vice-Chairman -
Sally Bennett -
Jean-Yves Blay -
Pascale Boissel -
Gilles Brisson - Véronique Chabernaud
-
Bpifrance Participations , represented byOlivier Martinez
About
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in
Learn more about
Information about
ISIN code |
FR0010331421 |
|
Ticker code |
Euronext: IPH Nasdaq: IPHA |
|
LEI |
9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005388/en/
Investors and Media
+33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Marie Puvieux (
+33 981 87 46 72
innate-pharma@atcg-partners.com
Source:
FAQ
Who is Dr. Sally Bennett as appointed to Innate Pharma's Supervisory Board?
What happened during Innate Pharma's AGM on May 20, 2022?
What is the impact of Dr. Sally Bennett's appointment on Innate Pharma?